| 研究成果： |
发表多篇SCI论文，如
1, 1，Si Dayong, Guo Yingjie, Zhang Yifan, Yang Lei, Zhou Hui, Zhong Dafang, Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics (Pharmacogenetics and Genomics). 2004 Jul;14(7):465-9. ；
2, 2，Dayong Si, Ying Wang, Yingjie Guo, Juan Wang, Hui Zhou, Yi-Han Zhou, Ze-Sheng Li, and John. Paul Fawcett, Mechanism of CYP2C9 inhibition by flavones and flavonols, Drug Metabolism and Disposition. 2009 Mar;37(3):629-34
3，3，Si Dayong, Wang Juan, Zhang Yifan, Zhong Da-Fang, Zhou Hui. Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2. Biopharm Drug Dispos. 2012 Sep;33(6):342-5.
4，4，Si Dayong; Wang Juan; Xu Ying; Chen Xiaoshuai; Zhang Mingqiu; Zhou Hui，Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol. J Cardiovasc Pharmacol. 2014 Oct;64(4):306-9
5，5，Yifan Zhang, Dayong Si, Xiaoyan Chen, Nan Lin, Yingjie Guo, Hui Zhou, Dafang Zhong*, Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. The British Journal of Clinical Pharmacology, 2007 Jul;64(1):67-74.
主持 国家自然科学基金青年科学基金，遗传多态性对第三代β受体阻滞剂降压疗效的影响及机理研究等项目2012.1-2014.12，等项目 |
